Safety concerns of sodium-glucose co-transporter-2 inhibitors in type 1 diabetes: A real-world study from the perspective of the Food and Drug Administration Adverse Event Reporting System.

HOME
>
論文・技術情報
>
Safety concerns of sodium-glucose co-transporter-2 inhibitors in type 1 diabetes: A real-world study from the perspective of the Food and Drug Administration Adverse Event Reporting System.

アブストラクト
ジャーナル名	Diabetes, obesity & metabolism
Pubmed追加日	2020/7/8
投稿者	Zhou, Xiang; Zhou, Yangzhong; Li, Xuemei; Xiao, Xinhua
組織名	Department of Endocrinology, Key Laboratory of Endocrinology of National Health;and Family Planning Commission, Peking Union Medical College Hospital, Chinese;Academy of Medical Science and Peking Union Medical College, Beijing, China.;Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy;of Medical Science and Peking Union Medical College, Beijing, China.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/32633000/